|
1
|
Ning M, Chunhua M, Rong J, Yuan L, Jinduo
L, Bin W and Liwei S: Diagnostic value of circulating tumor cells
in cerebrospinal fluid. Open Med (Wars). 11:21–24. 2016.PubMed/NCBI
|
|
2
|
Kawabe T, Phi JH, Yamamoto M, Kim DG,
Barfod BE and Urakawa Y: Treatment of brain metastasis from lung
cancer. Prog Neurol Surg. 25:148–155. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fidler IJ: The biology of brain
metastasis: challenges for therapy. Cancer J. 21:284–293. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Johung KL, Yeh N, Desai NB, Williams TM,
Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg
S, et al: Extended survival and prognostic factors for patients
with ALK-rearranged non-small-cell lung cancer and brain
metastasis. J Clin Oncol. 34:123–129. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jamal-Hanjani M and Spicer J: Epidermal
growth factor receptor tyrosine kinase inhibitors in the treatment
of epidermal growth factor receptor-mutant non-small cell lung
cancer metastatic to the brain. Clin Cancer Res. 18:938–944. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu WJ, Zeng XT, Qin HF, Gao HJ, Bi WJ and
Liu XQ: Whole brain radiotherapy plus chemotherapy in the treatment
of brain metastases from lung cancer: A meta-analysis of 19
randomized controlled trails. Asian Pac J Cancer Prev.
13:3253–3258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi Y, Sun Y, Yu J, Ding C, Ma Z, Wang Z,
Wang D, Wang Z, Wang M, Wang Y, et al: China experts consensus on
the diagnosis and treatment of brain metastases of lung cancer
(2017 version). Zhongguo Fei Ai Za Zhi. 20:1–13. 2017.(In Chinese).
PubMed/NCBI
|
|
8
|
Rahn DA III, Ray DK, Schlesinger DJ,
Steiner L, Sheehan JP, O'Quigley JM and Rich T: Gamma knife
radiosurgery for brain metastasis of nonsmall cell lung cancer: Is
there a difference in outcome between morning and afternoon
treatment? Cancer. 117:414–420. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peacock KH and Lesser GJ: Current
therapeutic approaches in patients with brain metastases. Curr
Treat Options Oncol. 7:479–489. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pan HC, Sheehan J, Stroila M, Steiner M
and Steiner L: Gamma knife surgery for brain metastases from lung
cancer. J Neurosurg. 102 Suppl:128–133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gerosa M, Nicolato A, Foroni R, Tomazzoli
L and Bricolo A: Analysis of long-term outcomes and prognostic
factors in patients with non-small cell lung cancer brain
metastases treated by gamma knife radiosurgery. J Neurosurg. 102
Suppl:75–80. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ortuzar W, Hanna N, Pennella E, Peng G,
Langer C, Monberg M and Scagliotti G: Brain metastases as the
primary site of relapse in two randomized phase III pemetrexed
trials in advanced non-small-cell lung cancer. Clin Lung Cancer.
13:24–30. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shimizu T, Nakanishi Y, Nakagawa Y,
Tsujino I, Takahashi N, Nemoto N and Hashimoto S: Association
between expression of thymidylate synthase, dihydrofolate
reductase, and glycinamide ribonucleotide formyltransferase and
efficacy of pemetrexed in advanced non-small cell lung cancer.
Anticancer Res. 32:4589–4596. 2012.PubMed/NCBI
|
|
14
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi Y, Sun Y, Ding C, Wang Z, Wang C, Bai
C, Bai C, Feng J, Liu X, Li F, et al: China experts consensus on
icotinib for non-small cell lung cancer treatment (2016 version).
Zhongguo Fei Ai Za Zhi. 19:489–494. 2016.(In Chinese). PubMed/NCBI
|
|
16
|
Wang XF, Wu YH, Wang MS and Wang YS: CEA,
AFP, CA125, CA153 and CA199 in malignant pleural effusions predict
the cause. Asian Pac J Cancer Prev. 15:363–368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagashima T, Sakao Y, Mun M, Ishikawa Y,
Nakagawa K, Masuda M and Okumura S: A clinicopathological study of
resected small-sized squamous cell carcinomas of the peripheral
lung: Prognostic significance of serum carcinoembryonic antigen
levels. Ann Thorac Cardiovasc Surg. 19:351–357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kulpa J, Wójcik E, Reinfuss M and
Kołodziejski L: Carcinoembryonic antigen, squamous cell carcinoma
antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell
lung cancer patients. Clin Chem. 48:1931–1937. 2002.PubMed/NCBI
|
|
19
|
Sertić Milić H, Franjević A, Bubanović G,
Marušić A, Nikolić I and Puljić I: Size, edge, and stage of NSCLC
determine the release of CYFRA 21-1 in bloodstream. Wien Klin
Wochenschr. 127:465–471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Szturmowicz M, Rudziński P, Kacprzak A,
Langfort R, Bestry I, Broniarek-Samson B and Orłowski T: Prognostic
value of serum C-reactive protein (CRP) and cytokeratin 19
fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in
surgically treated patients with non-small cell lung cancer.
Pneumonol Alergol Pol. 82:422–429. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ramalingam S and Belani C: Systemic
chemotherapy for advanced non-small cell lung cancer: recent
advances and future directions. Oncologist. 13 Suppl 1:5–13. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Muallaoglu S, Disel U, Mertsoylu H, Besen
A, Karadeniz C, Taner Sumbul A, Abali H and Ozyilkan O: Acute
infusion reactions to chemotherapeutic drugs: a single institute
experience. J BUON. 18:261–267. 2013.PubMed/NCBI
|
|
23
|
Lindvall P, Bergström P, Löfroth PO,
Henriksson R and Bergenheim AT: Hypofractionated conformal
stereotactic radiotherapy alone or in combination with whole-brain
radiotherapy in patients with cerebral metastases. Int J Radiat
Oncol Biol Phys. 61:1460–1466. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park SJ, Kim HT, Lee DH, Kim KP, Kim SW,
Suh C and Lee JS: Efficacy of epidermal growth factor receptor
tyrosine kinase inhibitors for brain metastasis in non-small cell
lung cancer patients harboring either exon 19 or 21 mutation. Lung
Cancer. 77:556–560. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Al-Saleh K, Quinton C and Ellis PM: Role
of pemetrexed in advanced non-small-cell lung cancer: meta-analysis
of randomized controlled trials, with histology subgroup analysis.
Curr Oncol. 19:e9–e15. 2012.PubMed/NCBI
|
|
26
|
Arrieta O, Villarreal-Garza C,
Martínez-Barrera L, Morales M, Dorantes-Gallareta Y, Peña-Curiel O,
Contreras-Reyes S, Macedo-Pérez EO and Alatorre-Alexander J:
Usefulness of serum carcinoembryonic antigen (CEA) in evaluating
response to chemotherapy in patients with advanced non small-cell
lung cancer: a prospective cohort study. BMC Cancer. 13:2542013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hoang T, Xu R, Schiller JH, Bonomi P and
Johnson DH: Clinical model to predict survival in chemonaive
patients with advanced non-small-cell lung cancer treated with
third-generation chemotherapy regimens based on eastern cooperative
oncology group data. J Clin Oncol. 23:175–183. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Muley T, Fetz TH, Dienemann H, Hoffmann H,
Herth FJ, Meister M and Ebert W: Tumor volume and tumor marker
index based on CYFRA 21-1 and CEA are strong prognostic factors in
operated early stage NSCLC. Lung Cancer. 60:408–415. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo J, Yu J, Song X and Mi H: Serum CA125,
CA199 and CEA combined detection for epithelial ovarian cancer
diagnosis: A meta-analysis. Open Med (Wars). 12:131–137.
2017.PubMed/NCBI
|
|
30
|
Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH
and Goldman ID: The proton-coupled folate transporter: Impact on
pemetrexed transport and on antifolates activities compared with
the reduced folate carrier. Mol Pharmacol. 74:854–862. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chattopadhyay S, Moran RG and Goldman ID:
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and
clinical applications. Mol Cancer Ther. 6:404–417. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tiseo M, Giovannetti E, Tibaldi C,
Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A,
Peters GJ, Smit EF and Ardizzoni A: Pharmacogenetic study of
patients with advanced non-small cell lung cancer (NSCLC) treated
with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer.
78:92–99. 2012. View Article : Google Scholar : PubMed/NCBI
|
